(Q35075780)

6 August 2017

1 reference

title

Big physics, small doses: the use of AMS and PET in human microdosing of development drugs (English)

1 reference

6 August 2017

Graham Lappin

1

1 reference

6 August 2017

R Colin Garner

series ordinal

2

1 reference

6 August 2017

publication date

1 March 2003

1 reference

Nature Reviews Drug Discovery

6 August 2017

published in

1 reference

6 August 2017

volume

2

1 reference

6 August 2017

issue

3

1 reference

6 August 2017

page(s)

233-240

1 reference

Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985)

6 August 2017

cites work

1 reference

Integration of virtual and high-throughput screening

21 January 2018

1 reference

High-throughput crystallography for lead discovery in drug design.

21 January 2018

1 reference

Recombinant yeast in drug metabolism.

21 January 2018

1 reference

The use of in vitro methods to predict in vivo pharmacokinetics and drug interactions

21 January 2018

1 reference

High-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry

21 January 2018

1 reference

Interspecies scaling: predicting volumes, mean residence time and elimination half-life. Some suggestions.

21 January 2018

1 reference

Pharmacokinetics and its role in small molecule drug discovery research

21 January 2018

1 reference

Allometric issues in drug development

21 January 2018

1 reference

Bioanalytical applications of accelerator mass spectrometry for pharmaceutical research

21 January 2018

1 reference

Accelerator mass spectrometry in biomedical dosimetry: relationship between low-level exposure and covalent binding of heterocyclic amine carcinogens to DNA

21 January 2018

1 reference

Accelerator mass spectrometry (AMS): recent experience of its use in a clinical study and the potential future of the technique

21 January 2018

1 reference

Use of positron emission tomography in analysing receptor function in vivo

21 January 2018

1 reference

Fundamentals of positron emission tomography and applications in preclinical drug development

21 January 2018

1 reference

A method of studying pharmacokinetics in man at picomolar drug concentrations

21 January 2018

1 reference

Pharmacokinetic evaluation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in patients by positron emission tomography

21 January 2018

1 reference

Evaluation of accelerator mass spectrometry in a human mass balance and pharmacokinetic study-experience with 14C-labeled (R)-6-[amino(4- chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1- methyl-2(1H)-quinolinone (R115777), a far

21 January 2018

1 reference

PET for in vivo pharmacokinetic and pharmacodynamic measurements

21 January 2018

1 reference

Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans

21 January 2018

1 reference

From the analyst's couch. Trends in development cycles

21 January 2018

1 reference

Risks in new drug development: approval success rates for investigational drugs

21 January 2018

1 reference

In vivo pharmacokinetics and pharmacodynamics in drug development using positron-emission tomography

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1038/NRD1037

1 reference

6 August 2017

1 reference